Title of article :
THE RELATION OF HYPERHOMOCYSTEINEMIA TO COGNITIVE FUNCTION and BRAIN ATROPHY IN PATIENTS WITH MULTIPLE SCLEROSIS
Author/Authors :
Ghaffarpour, M Department of Neurology - Iranian Center of Neurological Research - Imam Khomeini Hospital - School of Medicine - Medical Sciences/University of Tehran - Tehran, Iran , Harirchian, M.H Department of Neurology - Iranian Center of Neurological Research - Imam Khomeini Hospital - School of Medicine - Medical Sciences/University of Tehran - Tehran, Iran , Maghbooli, M Department of Radiology - Imam Khomeini Hospital - School of Medicine - Medical Sciences/University of Tehran - Tehran, Iran , Ghabaie-Hashemi, H.M Department of Radiology - Imam Khomeini Hospital - School of Medicine - Medical Sciences/University of Tehran - Tehran, Iran
Abstract :
Cognitive impairment may be a common even at the onset of multiple sclerosis (MS). In
this case-control study, we tried to find out the probable relationship between homocysteine levels and
cerebral atrophy or cognitive impairment in patients with multiple sclerosis. One hundred fifty six
patients who had MS according to McDonald diagnostic criteria were included in this study. Patients’
age, gender, and educational level, MS duration and clinical type, disability, cognitive function state
based on minimental state examination (MMSE), presence of hyperhomocysteinemia, and brain atrophy
were evaluated. There was no statistically significant relationship between hyperhomocysteinemia and
cognitive status. Total homocysteine levels had a significant correlation with MMSE score only in those
patients with elementary level of education. Also total homocysteine levels and overall cerebral atrophy
did not indicate significant relationship according to those independent variables mentioned above
except in the patients with EDSS less than 6. When intercaudate ratio > 0.10 was applied as a criterion
for cerebral atrophy, we found that hyperhomocysteinemia related significantly to intercaudate ratio >
0.10 in females, aged between 21 and 30 years, MS duration ≤ 5 years, primary progressive MS and
relapsing-remitting MS clinical types, EDSS ≤ 3 and elementary level of education. We suggest
applying MMSE only for the first step of cognitive function survey. In the next steps, much more exact
test must be used (e.g. MSNQ). Also we can not suggest measuring plasma homocysteine level as
criterion for monitoring the cognitive function in patients with MS.
Keywords :
brain atrophy , cognitive function , hyperhomocysteinemia , Multiple sclerosis
Journal title :
Astroparticle Physics